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Objective: Hyperbilirubinemia is one of the most devastating pathologies induced by
various liver diseases. Formulae related to Paeoniae Radix Rubra (PRR) at high doses
have been applied to treat hyperbilirubinemia in traditional Chinese medicine (TCM). The
aim of this systematic review and meta-analysis is to assess the efficacy and safety of
formulae relevant to high-dose PRR in patients suffering from hyperbilirubinemia induced
by viral hepatitis.
Methods: We performed a meta-analysis of randomized-controlled clinical trials to
evaluate the efficacy and safety of formulae that apply a high dose of PRR for
hyperbilirubinemia. Seven databases were searched until April, 2015. All studies were
included according to detailed criteria and assessed for methodological quality. The
outcome measurements were recorded for further analysis using the RevMan 5.2.11
software.
Results: Fifteen articles involving 1323 patients with hyperbilirubinemia were included.
Formulae with high-dose PRR might promote the efficacy of either a combined
application ([OR: 3.98, 95% CI (2.91, 5.43)]; P < 0.01) or a single application ([OR:
4.00, 95% CI (1.50, 10.68)]; P < 0.01) for hyperbilirubinemia. The indices of TBIL, ALT,
and AST significantly decreased ([MD: –75.57, 95% CI (−94.88,−56.26)], [MD: −26.54,
95% CI (−36.19, −16.88)], and ([MD: −28.94, 95% CI (−46.26, −11.61)]; P < 0.01),
respectively. In addition, formulae with high-dose PRR could enhance the treatment
efficacy of hyperbilirubinemia triggered by hepatitis B ([OR: 2.98, 95% CI (1.75, 5.05)];
P < 0.01). Furthermore, the efficacy was enhanced with an increasing dosage of PRR.
Two articles reported that no side effects occurred in clinical trials, and three studies
noted that patients presented light digestive tract symptoms.
Conclusion: Formulae relevant to high-dose PRR ameliorate hyperbilirubinemia and
might constitute a promising therapeutic approach. For widespread acceptance by
practitioners, more rigorously designed multicenter, double-blind, randomized, and
large-scale controlled trials are required.
Keywords: Paeoniae Radix Rubra formulae, efficacy and safety, meta-analysis, hyperbilirubinemia, viral hepatitis,
high dose Paeoniae Radix Rubra
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INTRODUCTION
Hyperbilirubinemia presenting high serum bilirubin or severe
jaundice is one of the most devastating pathologies in patients
with various liver diseases (Duan et al., 2006). Continuous
hyperbilirubinemia without proper treatment commonly leads
to hepatocyte edema, necrosis, inflammation, and even liver
cirrhosis, which can directly threaten quality of life (Garg et al.,
2011). Current therapies for hyperbilirubinemia mainly focus on
a combination of decreasing serum bilirubin, liver protection,
regulating transaminase levels, and nutrition support. However,
there are unstable curative rates as well as side effects in the clinic.
Ursodeoxycholic acid (UDCA) and Ademetionine are the first-
line drugs used to decrease serum bilirubin. The inconsistent
efficiency and expensive medical costs are common obstacles for
some patients (Hou et al., 2010). Potassiummagnesium aspartate
as an adjuvant is limited by its efficacy in decreasing serum
bilirubin. In addition, glucocorticosteroid therapy, due to side
effects and the possibility of symptom rebound, is controversial,
particularly when treating hyperbilirubinemia for a long duration
(Zhang and Shen, 2011).
Growing evidence indicates that traditional Chinese medicine
(TCM), as a complementary and alternative therapy, has an
important role in hyperbilirubinemia or jaundice treatment (Li
et al., 2008). The decoctions of Yin Chen Hao, Yin Chen Si Ni,
Da Huang Xiao Shi, Zhi Zi Bai Pi, and Chi Dan Tui Huang
have been proven to effectively decrease serum bilirubin and
protect hepatocytes (He et al., 2003; Zhou, 2010). In particular,
several formulae that reverse blood stasis are commonly applied
in hyperbilirubinemia. Paeoniae Radix Rubra (PRR, Chishao in
Chinese), the dried root of Paeonia lactiflora Pall, has been used
for thousands of years in TCM to treat blood stasis. A series
of PRR-relevant formulae, due to their significant function as
blood invigorators, have been used as treatments for jaundice
for decades and have obtained satisfactory efficacy (Ding et al.,
2003). Currently, these formulae have been reported as promising
therapies in the clinic and are widely used in China. However,
a systematic review on formulae relevant to high-dose PRR for
treating hyperbilirubinemia has not been reported. Therefore,
this meta-analysis of randomized controlled trials (RCTs) was
conducted to assess the clinical value of formulae relevant to
high-dose PRR in treating hyperbilirubinemia and to provide a
possible complementary and alternative therapy for widespread
use by practitioners (Figure 1).
METHODS
Search Strategy
Comprehensive searches were performed in seven databases
by two researchers. The databases included PubMed, Embase,
Abbreviations: PRR, Paeoniae Radix Rubra; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; TBIL, total bilirubin; UDCA, ursodeoxycholic acid;
TCM, traditional Chinese medicine; RCTs, randomized control trials; VMIS,
VIP medicine information system; CBM, Chinese Biomedical Database; CNKI,
China National Knowledge Infrastructure; VHPTP, Viral Hepatitis Prevention and
Treatment Programs; γ-GT, γ-glutamyl transferase; DBIL, direct bilirubin; PT,
prothrombin time; MD, mean difference; OR, odds ratio.
Cochrane Library, Chinese Biomedical Database (CBM),
Wanfang, VIP medicine information system (VMIS), and China
National Knowledge Infrastructure (CNKI) from inception
to April, 2015. Search terms included “TCM” or “PRR” or
“Chishao” “Paeonia lactiflora pall” or “Paeonia veitchii Lynch”,
and “severe jaundice,” or “hyperbilirubinemia,” and “viral
hepatitis” according to databases in the Chinese and English
languages. The first author, year of publication, title, and journal
name from searched articles were recorded.
Exclusion Criteria
Studies with the following criteria were excluded: (1) reviews,
non-clinical studies, and case observations, (2) the absence of
Randomized controlled trials (RCTs), or (3) interventions with
another TCM formulae (not including extracted agents) or
acupuncture therapies in the control group.
Inclusion Criteria
According to the advice of a liver specialist, the inclusion
criteria were designed as follows: (1) RCTs with patients
diagnosed as having hyperbilirubinemia by meeting the criteria
of Viral Hepatitis Prevention and Treatment Programs (VHPTP)
version 2010, 2005, 2000, 1995, or 1990. (2) Studies must
have claimed that patients developed hyperbilirubinemia due to
viral hepatitis. In addition, participant serum TBIL was above
171 µmol/L before treatment. (3) PRR served as the main
component in the formulae and the high dosage was defined
as >25 g (two times higher than the prescribed maximum dose
of Chinese Pharmacopeia 2010 version). (4) High-dose PRR-
relevant formulae alone or as a combined application served as
the trial group. Placebo or conventional therapy served as the
control group. (5) Outcome measurements must have included
one or more of the following indices: total effective rate, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), total
bilirubin (TBIL), direct bilirubin (DBIL), γ-glutamyl transferase
(γ-GT), albumin (ALB), and prothrombin time (PT). (6) The
total efficacy was coincident with the Guidance for Clinical
Research on New Drugs of TCM, i.e., recovery as evidenced by
the absence of symptoms and TBIL decreasing to nearly normal
levels. Effectiveness was identified by ameliorated symptoms and
TBIL decreasing below half of the original value (85.5 µmol/L).
Invalidation was defined as symptoms and TBIL remaining
unchanged or worsening.
Data Extraction and Risk of Bias
Assessment
Data extraction and quality assessment were independently
performed by two researchers, and disagreements were resolved
by consensus. Detailed data such as study design, participants’
information, interventions, outcome measures, and adverse
events were extracted to a conclusive table.
The Cochrane risk of bias tool was used to access the
methodological quality of the included RCTs. There were six
domains, including random sequence generation (selection bias),
allocation concealment (selection bias), blinding of participants
and personnel (performance bias), blinding of outcome data
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FIGURE 1 | Study flow of Paeoniae Radix Rubra in hyperbilirubinemia. It demonstrated that PRR has been used for the treatment of blood stasis for hundreds
of years, as evidenced by records from Ben Cao Gang Mu in 1578 (Ming dynasty). This study was performed to assess the clinical value of high-dose PRR-relevant
formulae in the treatment of hyperbilirubinemia.
(attrition bias), incomplete outcome data (attrition bias), and
selective reporting (reporting bias).
Data Analysis
Statistical analysis was performed using Cochrane RevMan 5.2.11
(Cochrane Collaboration). Dichotomous data were presented
as the odds ratio (OR) and continuous variables as the mean
difference (MD) with 95% confidence intervals (95% CI).
Statistical heterogeneity was assessed by Cochrane’s Q-test. Data
with low heterogeneity (P≥ 0.10 and I2 ≤ 50%) were analyzed by
a fixed-effects model, whereas a random-effect model was used
for data with high heterogeneity. A funnel plot was used to assess
potential publication bias.
RESULTS
Characteristics of the Included Studies
A total of 4300 publications from 7 databases were identified
for the initial screen. We removed 1278 duplicated citations,
and 2780 were excluded due to irrelevance. The full texts of 242
articles were retrieved for detailed assessment. Of the remaining
articles, there were 57 non-randomized controlled studies, 6
animal studies, 97 inconsistent criteria, 40 ineligible PRR doses
in the formulae or no mention of dosage, 14 with no PRR in the
formulae, 8 summaries, and 5 review articles. Fifteen studies were
ultimately used for further meta-analysis (Figure 2).
Fifteen articles involving 1323 subjects with
hyperbilirubinemia (729 cases in the trial group, 594 cases
in the control group) were included in this study. Because most
of the formulae-form therapy was applied in TCM, the 15 studies
that had been screened were all published in Chinese. There
was no significance in terms of age and sex between these two
groups (Table 1). Formulae with high-dose PRR with essential
treatment or as a single application were used in the trial group,
whereas essential treatment was applied in the control group in
all studies. The dose of PRR in the formulae ranged from 30 to
200 g. The treatment duration described in the articles ranged
from 2 weeks to 60 days, and 5 articles (Li and Gu, 1994; Xu
et al., 1999; Wang et al., 2003; Lou et al., 2007; Bo, 2008) reported
adverse events and side effects. No trial reported a follow-up
(Table 2).
Methodological Quality of Included Trials
Themethodological quality of the 15 included trials was generally
low. According to the Cochrane risk of bias estimation, a
randomized allocation of participants was mentioned in all
trials. However, only 2 trials (Huang and Yang, 2005; Zhang,
2009) mentioned an appropriate randomized method. Allocation
concealment, blinding of participants and blinding of outcome
assessment were not recorded in the 15 studies. Six of the 15
articles (Feng et al., 2006; Lou et al., 2007; Luo, 2007; Shi et al.,
2009; Zhang, 2009; He, 2010) were at low risk of incomplete
outcome data or essential data missing. Selective reporting was
generally unclear. Only four articles (Li and Gu, 1994; Wang
et al., 2003; Luo, 2007; Bo, 2008) reported research protocols, and
the result of the detailed indices indicated a low risk of selective
reporting. (Figure 3).
Outcome Measures with Subgroup
Analysis
Efficacy Rate of High-Dose PRR-Relevant Formulae
Combined with Essential Treatment or Single
Application vs. Essential Treatment
Thirteen of the 15 articles described the application of formulae
on high-dose PRR combined with essential treatment as the
trial group. The remaining 2 RCTs (Liu, 2000; Shi et al., 2009)
reported a single application of high-dose PRR formulae in the
trial group. No heterogeneity was found in both analyses and a
fixed effects model was used (P > 0.10). The results displayed
as OR with 95% CI in the combination treatment and single
application were [OR: 3.98, 95% CI (2.91, 5.43)] and [OR: 4.00,
95% CI (1.50, 10.68)], respectively. This revealed that formulae
of high-dose PRR might promote the treatment efficacy for
hyperbilirubinemia (P < 0.01; Figure 4).
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TABLE 1 | Characteristics of included studies.
Author and published year(reference) Cases T/C Diagnostic standard Age(years) Sex
Range, mean Male/female
He, 2010 36/27 VHPTP(2005)+TBIL T:9–62, 36 T:27/9
C:13–65, 42 C:16/11
Shi et al., 2009 53/50 VHPTP(2000)+TBIL T:45.3 T:28/25
C:46.9 C:27/23
Zhang, 2009 64/40 VHPTP(2000)+TBIL T:18–56, 41 T:40/24
C:19–58, 43 C:28/12
Bo, 2008 40/40 VHPTP(2000)+TBIL T:20–63, 44.4 T:30/10
C:18–62, 46.3 C:28/12
Luo, 2007 31/30 VHPTP(2000)+TBIL T:21–50, 35.6 T:20/11
C:22–52, 36.7 C:20/10
Luo, 2007 30/25 VHPTP(2000)+TBIL T: 26–62, 36.3 T:23/7
C:25–60, 34.2 C:21/4
Feng et al., 2006 60/60 VHPTP(2000)+TBIL T:38.6 T:45/15
C:37.8 C:47/13
Han et al., 2006 45/35 VHPTP(2000)+TBIL T/C:41.9 65/15
Zhu et al., 2006 56/44 VHPTP(2000)+TBIL T:33.5 T:45/11
C:34.2 C:38/6
Huang and Yang, 2005 72/37 VHPTP(2000)+TBIL T:19–58, 40.5 T:46/26
C:18–56, 38.6 C:23/14
Kong et al., 2003 50/32 VHPTP(1995)+TBIL T:12–74, 45.7 T:44/6
C:14–72, 46.9 C:28/4
Wang et al., 2003 48/42 VHPTP(2000)+TBIL 37 NR
Liu, 2000 43/43 VHPTP(1990)+TBIL T/C:12–58, 36 60/26
Xu et al., 1999 60/48 VHPTP(1995)+TBIL T:22/58, 41 T:44/16
C:21–56, 38 C:32/16
Li and Gu, 1994 41/41 VHPTP(1990)+TBIL T/C:18–50 T:28/13
C:27/14
T, trial group; C, control group. NR, no report.
Hyperbilirubinemia Indices of High-Dose
PRR-Relevant Formulae vs. Essential Treatment
The serum TBIL level, which is the direct and crucial index
of hyperbilirubinemia, was described in 12 trials. In addition,
3 studies (Huang and Yang, 2005; Lou et al., 2007; Zhang,
2009) reported the serum DBIL level. The serum ALT level was
measured in 11 articles, and five studies (Huang and Yang, 2005;
Feng et al., 2006; Lou et al., 2007; Shi et al., 2009; Zhang, 2009)
recorded the AST level. Serum ALB and γ-GT were reported in 4
(Kong et al., 2003;Wang et al., 2003; Luo, 2007; Bo, 2008) and two
trials (Feng et al., 2006; Shi et al., 2009), respectively. Two trials
(Kong et al., 2003;Wang et al., 2003) recorded the PT level. There
was heterogeneity in the indices of TBIL, DBIL, ALT, AST, PT,
and ALB (P < 0.10). Therefore, a random effects model was used
for analysis. There was no heterogeneity (P> 0.10) in the index of
γ-GT; the fixed-effect model was thus used. TheMDwith 95% CI
of serum TBIL, ALT, and AST levels were [MD: −75.57, 95% CI
(−94.88,−56.26)], [MD:−26.54, 95% CI (−36.19,−16.88)], and
[MD: −28.94, 95% CI (−46.26,−11.61)], respectively, indicating
a significant decrease in the pathologic index in the trial group
compared with the control group (P < 0.01). The indices of
serum DBIL, γ-GT, and PT were [MD: −28.41, 95% CI (−57.81,
0.99)], [MD: −0.03, 95% CI (−12.95, 12.89)], and [MD: −1.29,
95% CI (−3.33, 0.74)], respectively. There were no significant
decreases in the trial group compared with the control group
(P > 0.05). There was no difference between the trial group
and control group for the serum index [MD: ALB 1.84, 95% CI
(−0.14, 3.82)] (P > 0.05; Figures 5–7).
Efficacy Rate of High-Dose PRR-Relevant Formulae
Combined with Essential Treatment vs. Essential
Treatment in Hyperbilirubinemia Patients with
Hepatitis B
Hepatitis B virus is the most common and important cause of
hyperbilirubinemia. In this study, the efficacy rate of formulae
of high-dose PRR combined with essential treatment was
specifically analyzed. There were five articles (Feng et al., 2006;
Lou et al., 2007; Luo, 2007; Zhang, 2009; He, 2010) that reported
hyperbilirubinemia patients with hepatitis B virus. Based on the
fixed effects model (P > 0.10), the OR with 95% CI was [OR:
2.98, 95% CI (1.75, 5.05)]. The efficacy rate showed a significant
increase in the trial group compared with the control group
(Figure 8).
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TABLE 2 | Intervention and outcome measures of included studies.
Study ID Intervention Duration/follow
up
Adverse events Outcome measures
Trials group (high-dose
PRR-relevant formulae)
Control group (essential
treatment)
He, 2010 Tui Huang Decoction (PRR
60 g)+Essential treatment
Diammonium glycyrrhizinate
+Vitamin+Inosine+Ku
Huang injection potassium
magnesium
aspartate+Reduced
glutatione
6 weeks/NR NR Total efficacy rate, ALT,
TBIL
Shi et al., 2009 Qing Re Liang Xue Jie Du
Decoction (PRR 30 g)
Hepatocyte growth
promotion +Liver
protection+Improving
minicirculation
2 weeks/NR NR Total efficacy rate, ALT,
AST, TBIL, γ-GT, PT
Zhang, 2009 Tui Huang Decoction (PRR
30 g)+Essential treatment
Diammonium glycyrrhizinate
+Inosine+Vitamin+Reduced
glutatione+glucuronolactone
30 days/NR NR Total efficacy rate, ALT,
AST, TBIL, DBIL
Bo, 2008 Jia Wei Wen Dan
Decoction (PRR 30
g)+Essential treatment
Diammonium glycyrrhizinate
+Potassium magnesium
aspartate+Vitamin
30 days/NR NO Total efficacy rate, ALT,
ALB, TBIL
Luo, 2007 Tui Huang Decoction (PRR
30 g)+Essential treatment
Diammonium glycyrrhizinate
+Potassium magnesium
aspartate+Vitamin
6 weeks/NR T: 1 case diarrhea C: NO Total efficacy rate, ALT,
AST, TBIL, DBIL
Luo, 2007 Jie Du Huo Xue Decoction
(PRR 60 g)+Essential
treatment
Diammonium glycyrrhizinate
+Potassium magnesium
aspartate +Reduced
glutatione
30 days/NR NR Total efficacy rate, ALT,
TBIL, ALB
Feng et al., 2006 Da Huang Chi Shao
Decoction (PRR 30-60
g)+Essential treatment
Liver Protection+symptom
Treatment
60 days/NR NR Total efficacy rate, ALT,
AST, TBIL, γ-GT
Han et al., 2006 Chi Ze Decoction (PRR
100 g) +Essential
treatment
Liver Protection+symptom
Treatment
1 month/NR NR Total efficacy rate, ALT,
TBIL
Zhu et al., 2006 PRR 200 g+Essential
treatment
Dan Shen injection+Vitamin 1 month/NR NR Total efficacy rate
Huang and Yang, 2005 Liang Xue Hua Yu
Decoction(PRR 50
g)+Essential treatment
Vitamin+Hepatocyte
growth-promoting
factors+Potassium
magnesium aspartate+ALB
30 days/NR NR Total efficacy rate, ALT,
AST, TBIL, DBIL
Kong et al., 2003 PRR Relevant
Formulae(PRR 30-60
g)+Essential treatment
Diammonium glycyrrhizinate
+Potassium magnesium
aspartate+Vitamin+Hepatocyte
growth-promoting factors
6 weeks/NR NR Total efficacy rate, ALT,
TBIL, ALB, PT
Wang et al., 2003 Tui Gao Huang
Decoction(PRR 120
g)+Essential treatment
Vitamin+Adenosine
disodiu+Yin Zhi Huang
injection
4 weeks/NR T: Few with light digestive
tract side effect C: NO
Total efficacy rate, ALT,
TBIL, ALB, PT
Liu, 2000 PRR relevant
formulae(PRR 100–150 g)
Potassium magnesium
aspartate
+Vitamin+Bifendate
2 weeks/NR NR Total efficacy rate
Xu et al., 1999 Chi Zhi Huang
Decoction(PRR 90
g)+Essential treatment
Potassium magnesium
aspartate
+Vitamin+Adenosine
Disodiu+Glucuronolactone+
Silymarin
30 days/NR T: Few with light digestive
tract side effect C: NO
Total efficacy rate
Li and Gu, 1994 PRR relevant
formulae(PRR 60–120
g)+Essential treatment
Silymarin+Vitamin+Inosine+
Potassium magnesium
aspartate+Yin Zhi Huang
injection
30 days/NR NO Total efficacy rate, TBIL
T, trial group, C, control group. NR, no report.
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FIGURE 2 | Flow diagram of the study selection process for the
systematic review. As shown, our initial searches yielded 4300 records. The
full texts of 242 articles were retrieved for detailed assessment after exclusion.
Of these, 227 studies were subsequently excluded because they did not meet
the inclusion criteria; 15 eligible studies were identified.
Efficacy Rate of Different Ranges of High-Dose
PRR-Relevant Formulae Combined with Essential
Treatment vs. Essential Treatment in
Hyperbilirubinemia
Because there was a wide range of high-dose PRR from 30 to 200
g, a subgroup analysis of different ranges of formulae of high-dose
PRR was needed. We classified these studies into three subgroups
(PRR in 30–60 g, PRR in 60–120 g, and PRR greater than 120 g)
according to the dose application. There were six studies (Kong
et al., 2003; Huang and Yang, 2005; Feng et al., 2006; Lou et al.,
2007; Bo, 2008; Zhang, 2009) ascribed to the 30–60 g subgroup
and five studies (Li and Gu, 1994; Xu et al., 1999; Han et al.,
2006; Luo, 2007; He, 2010) ascribed to the 60–120 g subgroup. In
addition, the remaining 2 studies (Wang et al., 2003; Zhu et al.,
2006) were classified to the PRR greater than 120 g subgroup. On
the basis of the fixed effect model (P > 0.10), the ORs with 95%
CI of the three subgroups were [OR: 3.46, 95% CI (2.23, 5.37)]
(PRR in 30–60 g), [OR: 3.76, 95% CI (2.12, 6.69)] (PRR in 60–
120 g), and [OR: 6.15, 95% CI (3.03, 12.47)] (PRR more than 120
g), respectively. All three of the subgroups showed a significant
increase in the efficacy rate of the trial group compared with the
control group (P< 0.01). Furthermore, the efficacy was enhanced
with an increasing dosage of PRR in relevant formulae (Figure 9).
Adverse Events
Among the 15 RCTs, two articles (Li and Gu, 1994; Bo, 2008)
reported no side effects in clinical trials. Another three studies
(Xu et al., 1999; Wang et al., 2003; Lou et al., 2007) observed
side effects as light digestive tract symptoms in patients treated
with formulae of high-dose PRR. However, the side effect did not
influence the patients’ efficacy or daily life. The remaining articles
did not report whether there was a side effect. Despite the results
suggesting that high-dose PRR is safe, more assessments on the
safety of high-dose PRR are needed (Table 2).
Publication Bias
A funnel plot was used to express the publication bias. The
publication bias was explored when the indices or efficacy rate
were above 9 cases. A funnel plot of the formulae of high-dose
PRR combined with essential treatment vs. essential treatment
was applied. Further, the indices of TBIL and ALT were also
analyzed. The plots were symmetric, suggesting that there was no
obvious publication bias (Figure 10).
DISCUSSION
As we mentioned, cholestatic hepatitis, and hyperbilirubinemia
are both related to the dysfunction of bilirubin metabolism.
However, there are several differences between cholestatic
hepatitis. Cholestatic hepatitis is more concerned about the
whole progression of the disease which could result in partial
or complete blocking bile flow, high serum concentrations
of bile acid, bilirubin, and liver injury. On the other side,
hyperbilirubinemia could be widely expressed during the specific
progression of various liver diseases and is more focused on
the manifestation of high bilirubin. Moreover, the degree of
bilirubin in hyperbilirubinemia is usually far more severe than in
cholestatic hepatitis. In our former research, we have investigated
the effect of high dose PRR relevant formulae on cholestatic
hepatitis and found that this therapy could promote the efficacy
(Ma et al., 2014). Therefore, according to the former result, we
performed this meta-analysis on hyperbilirubinemia triggered
by viral hepatitis. This systematic review included 15 RCTs; a
total of 1323 participants with hyperbilirubinemia were screened
from 4300 publications. All of the studies were based on high-
dose PRR (30–200 g) serving as the primary component of the
formulae. The treatment duration described by the RCTs ranged
from 2 weeks to 60 days, and five of the 15 studies reported
side effects. According to the outcome, a single application or
a combination of high-dose PRR formulae promoted efficacious
hyperbilirubinemia treatment. The indices of hyperbilirubinemia
also verified the result. TBIL is considered a direct index of
hyperbilirubinemia. The serum TBIL level in 12 trials was
analyzed by the random effects model. The MD with the
95% CI of the serum TBIL level was [MD: −75.57, 95% CI
(−94.88, −56.26)] and indicated that formulae of high-dose
PRR significantly decreased the serum TBIL level compared with
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FIGURE 3 | Methodological quality assessment for risk of bias for each included study. Risk of bias was used to assess the quality of RCTs, and the majority
of studies were found to be of low quality.
FIGURE 4 | Forest plot of high-dose PRR-relevant formulae with essential treatment or single application vs. essential treatment in viral hepatitis
patients with hyperbilirubinemia. (1) Study item displayed as first author with the publication year. (2) Subgroups were divided by formulae combined with essential
treatment or single application. (3) I-squared and P are the criterion of the heterogeneity test,  pooled odds ratio, —— odds ratio, and 95% confidence interval.
essential treatment. Furthermore, the serum ALT and AST levels,
which are sensitive indices of hepatic function, also decreased.
However, there were no differences in DBIL, γ-GT, PT, and
ALB between the groups. This suggested that formulae of high-
dose PRR might promote the regulation of the main indices of
hyperbilirubinemia. Hepatitis B virus is the most common and
important cause of hyperbilirubinemia. Therefore, the efficacy
of high-dose PRR formulae on hyperbilirubinemia triggered by
hepatitis B was specifically analyzed in this study. The result
showed a significant increase in the efficacy rate in the trial group
compared with the control group. This suggested that formulae
of high-dose PRR might promote efficacious treatment of the
hyperbilirubinemia caused by hepatitis B. Because there was a
wide range of high-dose PRR, from 30 to 200 g, we performed
an analysis on the efficacy rate of different ranges of high-dose
PRR formulae. All three subgroups showed a significant increase
in the efficacy rate of the trial group. Furthermore, the efficacy
enhanced as the dosage of PRR in the relevant formulae was
increasing. There were a few patients with light side effects of the
digestive tract in the trial group. However, it did not influence
the treatment progress and efficacy. A funnel plot was applied
to assess the publication bias. The result indicated that little
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FIGURE 5 | Forest plot of TBIL, DBIL, ALT, AST, and PT in treatment. (1) Study item displayed as first author with the publication year. (2) Subgroups were
divided by indices of TBIL, DBIL, ALT, AST, and PT. (3) I-squared and P are the criterion of the heterogeneity test,  pooled mean difference, —— mean difference,
and 95% confidence interval.
publication bias occurred in terms of efficacy and indices. This
systematic review illustrates that formulae of high-dose PRR are
safe to promote the efficacious treatment of hyperbilirubinemia.
Hyperbilirubinemia, presenting with severe jaundice, is one
of the most common manifestations in viral hepatitis patients.
It usually leads to severe necrosis of hepatocytes over a chronic
period (Wang, 2010). It is well-known that a variety of definite
factors, including infection, drug abuse, autoimmunity, and
heredity, are able to cause hyperbilirubinemia. As for the
mechanism, researchers have mainly focused on disorders of
bilirubin metabolism such as uptake, synthesis, and excretion
(Nie, 2006). In detail, repeated inflammation in viral hepatitis
always acts as the trigger of jaundice and ultimately results in
hepatocyte damage and even necrosis. Once hepatocytes are
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FIGURE 6 | Forest plot of ALB in treatment. (1) Study item displayed as the first author with the publication year. (2) The index of serum ALB was assessed in
RCTs. (3) I-squared and P are the criterion of the heterogeneity test,  pooled mean difference, —— mean difference, and 95% confidence interval.
FIGURE 7 | Forest plot of γ-GT in treatment. (1) Study item displayed as the first author with the publication year. (2) The index of serum γ-GT was assessed in
RCTs. (3) I-squared and P are the criterion of the heterogeneity test,  pooled mean difference, —— mean difference, and 95% confidence interval.
FIGURE 8 | Forest plot of high dose PRR relevant formulae with essential treatment vs. essential treatment in hyperbilirubinemia patients with
hepatitis B. (1) Study item displayed as the first author with the publication year. (2) Specific analysis was performed for hepatitis B virus patients with
hyperbilirubinemia. (3) I-squared and P are the criterion of the heterogeneity test,  pooled odds ratio, —— odds ratio, and 95% confidence interval.
damaged, the metabolism of bilirubin is disturbed, thus causing
bilirubin accumulation. If the high concentration of bilirubin fails
to be eliminated, it accumulates such that hyperbilirubinemia or
jaundice occurs. Moreover, a micro-imbalance would also occur
in hepatocytes, such as inhibition of Na+-K+-ATPase, down
regulation of NTCP and OATP expression, and deregulation
of CAR and PXR expression. All of these consequences lead
to bilirubin deposition in hepatocytes and jaundice and can
cause worsening of hepatocyte damage (Paumgartner and Beuers,
2002; Wagner et al., 2011; Wlcek et al., 2013). According to
the mechanism, hyperbilirubinemia is associated with various
tissues and targets. Current western medical treatment for
hyperbilirubinemia mainly focuses on the combination of
alleviating jaundice, liver protection, lowering transaminase
levels, nutrition support, etc. However, it lacks comprehensive
adjustment and has unstable efficacy. In contrast, complementary
and alternative medicine such as TCM for the treatment of
hyperbilirubinemia often obtains positive results.
PRR has been widely used in TCM practice for thousands
of years for the treatment of blood stasis by targeting
the liver. Current studies indicate that PRR and its active
components consistently exhibit wide pharmacological effects
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FIGURE 9 | Forest plot of the different ranges of high-dose PRR-relevant formulae combined with essential treatment vs. essential treatment alone. (1)
Study item displayed as the first author with the publication year. (2) Subgroups were classified as PRR 30–60 g, PRR 60–120 g and PRR greater than 120 g. (3)
I-squared and P are the criterion of the heterogeneity test,  pooled odds ratio, —— odds ratio, and 95% confidence interval.
FIGURE 10 | Funnel plot of high-dose PRR-relevant formulae. (A) The plot of efficacy rate, (B) serum index of TBIL, and (C) serum index of ALT was symmetric,
suggesting that the publication bias was small.
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such as vasodilatation of the thoracic aorta (Jin et al., 2010),
liver protection (Zhao et al., 2013), an anti-allergic effect (Lee
et al., 2008), anti-inflammation, and immunoregulation (He
and Dai, 2011). According to the TCM theory and modern
pharmacology, the original clinical practice of formulae of
high-dose PRR to treat hyperbilirubinemia has been gradually
applied in recent years (Zhu, 2011). In addition, some studies
may partially reveal the mechanism of this application. PRR
is able to promote bile acid excretion, enhance the activity of
UDPGT and decrease the TXB2 level (Wang, 1986; Lei et al.,
1988). In this aspect, PRR is effective in decreasing bilirubin.
Although, there is efficacy on hyperbilirubinemia, it remains
unclear why PRR should be used at such a high dose. Clinical
studies have shown that there is a significant difference in
efficacy between the high-dose treatment group (30 g) and the
normal-dose treatment group (10 g). The efficacy of the high-
dose treatment group is markedly higher than the normal-dose
treatment group in alleviating hyperbilirubinemia (P < 0.01)
(Luo, 2007). This indicates that low-dose PRR cannot effectively
treat hyperbilirubinemia compared with a high dose. This is
likely related to the characteristic active compounds in PRR.
Our previous study demonstrated that the bioavailability of
paeoniflorin and albiflorin in PRR is extremely low (Jiang et al.,
2012). Herein, a high dose of PRR shows stable treatment efficacy
for the alleviation of hyperbilirubinemia, which was not found
at low doses. According to these results, formulae of high-dose
PRR might help uncover the crucial and specific function of this
therapy for hyperbilirubinemia.
Currently, increasing attention has focused on TCM. Due
to the holistic concept and treatment based on syndrome
differentiation, TCM emphasizes formulae employment instead
of a single drug application in treating diseases. Many studies
demonstrate that formulae with favorable efficacy for specific
diseases regulate body function in various organs and tissues in a
network manner (Li et al., 2007; Li and Zhang, 2013). Therefore,
further studies to illustrate the potential mechanism should be
explored.
CONCLUSION
Formulae of high-dose PRR might safely promote the
efficacious treatment of hyperbilirubinemia and are thus a
promising treatment approach. For acceptance by widespread
practitioners, more rigorously designed multicenter, double-
blind, randomized, and large-scale controlled trials are required
for further investigation.
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